234 related articles for article (PubMed ID: 11131539)
1. Gene transfer techniques for the delivery of GDNF in Parkinson's disease.
Ridet JL; Déglon N; Aebischer P
Novartis Found Symp; 2000; 231():202-15; discussion 215-9, 302-6. PubMed ID: 11131539
[TBL] [Abstract][Full Text] [Related]
2. Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model.
Björklund A; Kirik D; Rosenblad C; Georgievska B; Lundberg C; Mandel RJ
Brain Res; 2000 Dec; 886(1-2):82-98. PubMed ID: 11119690
[TBL] [Abstract][Full Text] [Related]
3. Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease.
Bilang-Bleuel A; Revah F; Colin P; Locquet I; Robert JJ; Mallet J; Horellou P
Proc Natl Acad Sci U S A; 1997 Aug; 94(16):8818-23. PubMed ID: 9238061
[TBL] [Abstract][Full Text] [Related]
4. Adenoviral vector-mediated delivery of glial cell line-derived neurotrophic factor provides neuroprotection in the aged parkinsonian rat.
Connor B
Clin Exp Pharmacol Physiol; 2001 Nov; 28(11):896-900. PubMed ID: 11703392
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson's disease.
Sun M; Kong L; Wang X; Lu XG; Gao Q; Geller AI
Brain Res; 2005 Aug; 1052(2):119-29. PubMed ID: 16018990
[TBL] [Abstract][Full Text] [Related]
6. Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease.
Lo Bianco C; Déglon N; Pralong W; Aebischer P
Neurobiol Dis; 2004 Nov; 17(2):283-9. PubMed ID: 15474365
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat.
Connor B; Kozlowski DA; Schallert T; Tillerson JL; Davidson BL; Bohn MC
Gene Ther; 1999 Dec; 6(12):1936-51. PubMed ID: 10637445
[TBL] [Abstract][Full Text] [Related]
8. Adenoviral vector-mediated GDNF gene therapy in a rodent lesion model of late stage Parkinson's disease.
Lapchak PA; Araujo DM; Hilt DC; Sheng J; Jiao S
Brain Res; 1997 Nov; 777(1-2):153-60. PubMed ID: 9449424
[TBL] [Abstract][Full Text] [Related]
9. Gene Therapy in the Management of Parkinson's Disease: Potential of GDNF as a Promising Therapeutic Strategy.
Behl T; Kaur I; Kumar A; Mehta V; Zengin G; Arora S
Curr Gene Ther; 2020; 20(3):207-222. PubMed ID: 32811394
[TBL] [Abstract][Full Text] [Related]
10. Efficient gene therapy for Parkinson's disease using astrocytes as hosts for localized neurotrophic factor delivery.
Drinkut A; Tereshchenko Y; Schulz JB; Bähr M; Kügler S
Mol Ther; 2012 Mar; 20(3):534-43. PubMed ID: 22086235
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologically controlled, discontinuous GDNF gene therapy restores motor function in a rat model of Parkinson's disease.
Tereshchenko J; Maddalena A; Bähr M; Kügler S
Neurobiol Dis; 2014 May; 65():35-42. PubMed ID: 24440408
[TBL] [Abstract][Full Text] [Related]
12. Sustained delivery of GDNF: towards a treatment for Parkinson's disease.
Zurn AD; Widmer HR; Aebischer P
Brain Res Brain Res Rev; 2001 Oct; 36(2-3):222-9. PubMed ID: 11690619
[TBL] [Abstract][Full Text] [Related]
13. Adenovirus-mediated transduction with human glial cell line-derived neurotrophic factor gene prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopamine depletion in striatum of mouse brain.
Kojima H; Abiru Y; Sakajiri K; Watabe K; Ohishi N; Takamori M; Hatanaka H; Yagi K
Biochem Biophys Res Commun; 1997 Sep; 238(2):569-73. PubMed ID: 9299553
[TBL] [Abstract][Full Text] [Related]
14. Adeno-associated virus type 2 vector-mediated glial cell line-derived neurotrophic factor gene transfer induces neuroprotection and neuroregeneration in a ubiquitin-proteasome system impairment animal model of Parkinson's disease.
Du Y; Zhang X; Tao Q; Chen S; Le W
Neurodegener Dis; 2013; 11(3):113-28. PubMed ID: 22626907
[TBL] [Abstract][Full Text] [Related]
15. Mutation analysis of the glial cell line-derived neurotrophic factor gene in Parkinson's disease.
Wartiovaara K; Hytönen M; Vuori M; Paulin L; Rinne J; Sariola H
Exp Neurol; 1998 Aug; 152(2):307-9. PubMed ID: 9710530
[TBL] [Abstract][Full Text] [Related]
16. Recombinant adeno-associated viral vector-mediated glial cell line-derived neurotrophic factor gene transfer protects nigral dopamine neurons after onset of progressive degeneration in a rat model of Parkinson's disease.
Mandel RJ; Snyder RO; Leff SE
Exp Neurol; 1999 Nov; 160(1):205-14. PubMed ID: 10630205
[TBL] [Abstract][Full Text] [Related]
17. Long-term glial cell line-derived neurotrophic factor overexpression in the intact nigrostriatal system in rats leads to a decrease of dopamine and increase of tetrahydrobiopterin production.
Sajadi A; Bauer M; Thöny B; Aebischer P
J Neurochem; 2005 Jun; 93(6):1482-6. PubMed ID: 15935064
[TBL] [Abstract][Full Text] [Related]
18. Pathogenesis of Parkinson's disease: prospects of neuroprotective and restorative therapies.
Fernandez-Espejo E
Mol Neurobiol; 2004 Feb; 29(1):15-30. PubMed ID: 15034220
[TBL] [Abstract][Full Text] [Related]
19. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease.
Kordower JH; Emborg ME; Bloch J; Ma SY; Chu Y; Leventhal L; McBride J; Chen EY; Palfi S; Roitberg BZ; Brown WD; Holden JE; Pyzalski R; Taylor MD; Carvey P; Ling Z; Trono D; Hantraye P; Déglon N; Aebischer P
Science; 2000 Oct; 290(5492):767-73. PubMed ID: 11052933
[TBL] [Abstract][Full Text] [Related]
20. Viral vectors in the treatment of Parkinson's disease.
Latchman DS; Coffin RS
Mov Disord; 2000 Jan; 15(1):9-17. PubMed ID: 10634236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
